These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

724 related items for PubMed ID: 22138067

  • 1. Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions.
    McCaughey G, McKevitt M, Elborn JS, Tunney MM.
    J Cyst Fibros; 2012 May; 11(3):163-72. PubMed ID: 22138067
    [Abstract] [Full Text] [Related]

  • 2. Resistance development of cystic fibrosis respiratory pathogens when exposed to fosfomycin and tobramycin alone and in combination under aerobic and anaerobic conditions.
    McCaughey G, Diamond P, Elborn JS, McKevitt M, Tunney MM.
    PLoS One; 2013 May; 8(7):e69763. PubMed ID: 23936095
    [Abstract] [Full Text] [Related]

  • 3. Antibiotic susceptabilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions.
    Hill D, Rose B, Pajkos A, Robinson M, Bye P, Bell S, Elkins M, Thompson B, Macleod C, Aaron SD, Harbour C.
    J Clin Microbiol; 2005 Oct; 43(10):5085-90. PubMed ID: 16207967
    [Abstract] [Full Text] [Related]

  • 4. Fosfomycin and tobramycin in combination downregulate nitrate reductase genes narG and narH, resulting in increased activity against Pseudomonas aeruginosa under anaerobic conditions.
    McCaughey G, Gilpin DF, Schneiders T, Hoffman LR, McKevitt M, Elborn JS, Tunney MM.
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5406-14. PubMed ID: 23959314
    [Abstract] [Full Text] [Related]

  • 5. Effect of oxygen limitation on the in vitro activity of levofloxacin and other antibiotics administered by the aerosol route against Pseudomonas aeruginosa from cystic fibrosis patients.
    King P, Citron DM, Griffith DC, Lomovskaya O, Dudley MN.
    Diagn Microbiol Infect Dis; 2010 Feb; 66(2):181-6. PubMed ID: 19828274
    [Abstract] [Full Text] [Related]

  • 6. Use of Calgary and Microfluidic BioFlux Systems To Test the Activity of Fosfomycin and Tobramycin Alone and in Combination against Cystic Fibrosis Pseudomonas aeruginosa Biofilms.
    Díez-Aguilar M, Morosini MI, Köksal E, Oliver A, Ekkelenkamp M, Cantón R.
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084746
    [Abstract] [Full Text] [Related]

  • 7. Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa.
    Herrmann G, Yang L, Wu H, Song Z, Wang H, Høiby N, Ulrich M, Molin S, Riethmüller J, Döring G.
    J Infect Dis; 2010 Nov 15; 202(10):1585-92. PubMed ID: 20942647
    [Abstract] [Full Text] [Related]

  • 8. In vitro activity of antibiotic combinations against Pseudomonas aeruginosa biofilm and planktonic cultures.
    Tré-Hardy M, Vanderbist F, Traore H, Devleeschouwer MJ.
    Int J Antimicrob Agents; 2008 Apr 15; 31(4):329-36. PubMed ID: 18280117
    [Abstract] [Full Text] [Related]

  • 9. Effect of oxygen limitation on the in vitro antimicrobial susceptibility of clinical isolates of Pseudomonas aeruginosa grown planktonically and as biofilms.
    Field TR, White A, Elborn JS, Tunney MM.
    Eur J Clin Microbiol Infect Dis; 2005 Oct 15; 24(10):677-87. PubMed ID: 16249934
    [Abstract] [Full Text] [Related]

  • 10. Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis.
    MacLeod DL, Barker LM, Sutherland JL, Moss SC, Gurgel JL, Kenney TF, Burns JL, Baker WR.
    J Antimicrob Chemother; 2009 Oct 15; 64(4):829-36. PubMed ID: 19679597
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Synergistic effects of aminoglycosides and fosfomycin on Pseudomonas aeruginosa in vitro and biofilm infections in a rat model.
    Cai Y, Fan Y, Wang R, An MM, Liang BB.
    J Antimicrob Chemother; 2009 Sep 15; 64(3):563-6. PubMed ID: 19561148
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Evaluation of long-term co-administration of tobramycin and clarithromycin in a mature biofilm model of cystic fibrosis clinical isolates of Pseudomonas aeruginosa.
    Tré-Hardy M, Traore H, El Manssouri N, Vanderbist F, Vaneechoutte M, Devleeschouwer MJ.
    Int J Antimicrob Agents; 2009 Oct 15; 34(4):370-4. PubMed ID: 19505804
    [Abstract] [Full Text] [Related]

  • 16. In vitro interactions of tobramycin with various nonantibiotics against Pseudomonas aeruginosa and Burkholderia cenocepacia.
    Treerat P, Widmer F, Middleton PG, Iredell J, George AM.
    FEMS Microbiol Lett; 2008 Aug 15; 285(1):40-50. PubMed ID: 18513356
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effect of antibiotic co-administration on young and mature biofilms of cystic fibrosis clinical isolates: the importance of the biofilm model.
    Tré-Hardy M, Macé C, El Manssouri N, Vanderbist F, Traore H, Devleeschouwer MJ.
    Int J Antimicrob Agents; 2009 Jan 15; 33(1):40-5. PubMed ID: 18801647
    [Abstract] [Full Text] [Related]

  • 19. In vitro prevention of Pseudomonas aeruginosa early biofilm formation with antibiotics used in cystic fibrosis patients.
    Fernández-Olmos A, García-Castillo M, Maiz L, Lamas A, Baquero F, Cantón R.
    Int J Antimicrob Agents; 2012 Aug 15; 40(2):173-6. PubMed ID: 22727530
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.